Abstract
The metal bonding properties of some ARA-II (Angiotensin II Receptor Antagonists) compounds, such as valsartan (VAL), were investigated by using spectrofluorimetric method. Fluorescence quenching of VAL by Cu(II) was studied and optimal experimental conditions were determined. The excitation and emission wavelengths were λex= 280 nm and λem= 436 nm for the Cu(II)-VAL complex in methanol medium. The calibration curve was obtained from Stern-Volmer equation plotting to F0/F-[Cu+2] graphs and the linearity was found within the range of 0.25-2.54 μg.ml-1 for the Cu(II)-VAL complex under optimal conditions. The detection limit (LOD) and the quantitation limits (LOQ) of the proposed method for this complex were 4.96 ng.ml-1 and 16.53 ng.ml-1 respectively. The stochiometry of this complex was also determined by using the continuous variation method and the molar ratio of Cu(II):VAL was calculated as 1:1. The interaction between the valsartan in tablet form and Cu(II) in the vitamin-mineral combination tablet was investigated by applying this quenching method and obtained satisfactory results.
Keywords: Valsartan, Cu(II) complex, fluorescence quenching, pharmaceutical analysis.
Current Drug Therapy
Title:Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Volume: 9 Issue: 4
Author(s): S. Beniz Gunduz and Ahmet Donertas
Affiliation:
Keywords: Valsartan, Cu(II) complex, fluorescence quenching, pharmaceutical analysis.
Abstract: The metal bonding properties of some ARA-II (Angiotensin II Receptor Antagonists) compounds, such as valsartan (VAL), were investigated by using spectrofluorimetric method. Fluorescence quenching of VAL by Cu(II) was studied and optimal experimental conditions were determined. The excitation and emission wavelengths were λex= 280 nm and λem= 436 nm for the Cu(II)-VAL complex in methanol medium. The calibration curve was obtained from Stern-Volmer equation plotting to F0/F-[Cu+2] graphs and the linearity was found within the range of 0.25-2.54 μg.ml-1 for the Cu(II)-VAL complex under optimal conditions. The detection limit (LOD) and the quantitation limits (LOQ) of the proposed method for this complex were 4.96 ng.ml-1 and 16.53 ng.ml-1 respectively. The stochiometry of this complex was also determined by using the continuous variation method and the molar ratio of Cu(II):VAL was calculated as 1:1. The interaction between the valsartan in tablet form and Cu(II) in the vitamin-mineral combination tablet was investigated by applying this quenching method and obtained satisfactory results.
Export Options
About this article
Cite this article as:
Gunduz Beniz S. and Donertas Ahmet, Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method, Current Drug Therapy 2014; 9 (4) . https://dx.doi.org/10.2174/1574885510999150505165817
DOI https://dx.doi.org/10.2174/1574885510999150505165817 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children
Reviews on Recent Clinical Trials Genomic Approaches and Oxygen Radical Measurement as Biomarker Candidates of Off-Season Predictor of Pollinosis: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Helicase Domain Containing Proteins in Human Disorders
Current Genomics Cationic Lipophilic Radiotracers for Functional Imaging of Multidrug Resistance
Current Radiopharmaceuticals The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Effects of Polysaccharides from Selenium-enriched Pyracantha fortuneana on Mice Liver Injury
Medicinal Chemistry Galanthus nivalis Agglutinin (GNA)-Related Lectins: Traditional Proteins, Burgeoning Drugs?
Current Chemical Biology AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Current Pharmaceutical Design Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Current Drug Targets Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Natural Polymers Based Hydrogels for Cell Culture Applications
Current Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry